Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS). (VANGARD)
A Randomized, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of Once Weekly Subcutaneous Injections of Pemziviptadil (PB1046), a Sustained-Release VIP (Vasoactive Intestinal Peptide) ANalogue, in Hospitalized COVID-19 Patients at HiGh Risk for Rapid Clinical Deterioration and ARDS (PB1046 VANGARD Study)
Sponsor: PhaseBio Pharmaceuticals Inc.
Terminated
Company no longer pursing indication
Other terminated trials from PhaseBio Pharmaceuticals Inc.
- Pulmonary Arterial Hypertension · Phase PHASE2 · Jan 2022
- Pulmonary Arterial Hypertension · Phase PHASE2 · Jan 2022
More terminations from PhaseBio Pharmaceuticals Inc.
Other Acute Respiratory Distress Syndrome trials with similar outcome
Listed as NCT04433546, this PHASE2 trial focuses on Acute Respiratory Distress Syndrome and COVID 19 and remains terminated or withdrawn. Sponsored by PhaseBio Pharmaceuticals Inc., it has been updated 8 times since 2020, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Nov 2020 — Dec 2020 [monthly]
Recruiting PHASE2
▶ Show 3 earlier versions
-
Oct 2020 — Nov 2020 [monthly]
Recruiting PHASE2
-
Aug 2020 — Oct 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jul 2020 — Aug 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- PhaseBio Pharmaceuticals Inc.
For direct contact, visit the study record on ClinicalTrials.gov .